These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New advice on switching antiepileptic drugs might be a false economy. Holmes E; Plumpton C; Duerden M; Marson T; Hughes D BMJ; 2013 Dec; 347():f7471. PubMed ID: 24342221 [No Abstract] [Full Text] [Related]
6. The pharmacoeconomics of the new antiepileptic drugs. Heaney D Epilepsia; 1999; 40 Suppl 8():25-31. PubMed ID: 10563592 [No Abstract] [Full Text] [Related]
7. New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included. Pierre-Louis SJ Arch Neurol; 2000 Feb; 57(2):272-3. PubMed ID: 10681089 [No Abstract] [Full Text] [Related]
8. The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications? Beghi E; Beghi M; Cornaggia CM Expert Rev Neurother; 2011 Dec; 11(12):1759-67. PubMed ID: 22091599 [TBL] [Abstract][Full Text] [Related]
9. [Some medical-social aspects of the therapy of epilepsy with drugs of new generation: financial side]. Gromov SA Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):59-61. PubMed ID: 11552639 [No Abstract] [Full Text] [Related]
10. The renaissance of rational polytherapy: the new generation of antiepileptic medications. Neurology; 1995 Mar; 45(3 Suppl 2):S35-8. PubMed ID: 7898744 [No Abstract] [Full Text] [Related]
11. Generic prescribing in epilepsy. Drug Ther Bull; 2009 Dec; 47(12):141-4. PubMed ID: 20009042 [TBL] [Abstract][Full Text] [Related]
12. [Social and economic aspects of administration of new antiepileptic drugs]. Dławichowska E; Owczarek K; Fiszer U Neurol Neurochir Pol; 2001; 35(2):245-52. PubMed ID: 11599223 [TBL] [Abstract][Full Text] [Related]
13. New drug treatments in epilepsy. Kuntzer T Eur Neurol; 1994; 34(1):4-10. PubMed ID: 8137837 [No Abstract] [Full Text] [Related]
14. How to use the new epilepsy drugs. Hall W Practitioner; 1995 Feb; 239(1547):125-8. PubMed ID: 7708616 [No Abstract] [Full Text] [Related]
15. Vision for the future. Beran R; Pachlatko C Epilepsia; 1999; 40 Suppl 8():55-6. PubMed ID: 10563597 [No Abstract] [Full Text] [Related]
16. Efficacy and tolerability of the new antiepileptic drugs: commentary on the recently published practice parameters. Panayiotopoulos CP; Benbadis SR; Covanis A; Dulac O; Duncan JS; Eeg-Olofsson O; Ferrie CD; Grünewald RA; Kasteleijn-Nolst Trenite DG; Koutroumanidis M; Martinovic Z; Newton RW; Parker AP; Salas-Puig J; Sander JW; Shorvon S; Watanabe K; Whitehouse WP; Youroukos S Epilepsia; 2004 Dec; 45(12):1646-9; author reply 1649-51. PubMed ID: 15571526 [No Abstract] [Full Text] [Related]
17. Use of phenobarbitone for treating childhood epilepsy in resource-poor countries. Wilmshurst JM; van Toorn R S Afr Med J; 2005 Jun; 95(6):392, 394, 396. PubMed ID: 16100884 [No Abstract] [Full Text] [Related]
18. Guidelines--are they useful? Ben-Menachem E; French JA Epilepsia; 2006; 47 Suppl 1():62-4. PubMed ID: 17044829 [TBL] [Abstract][Full Text] [Related]
19. [The "cost-benefit" analysis of new antiepileptic drugs]. Vlasov PN; Orekhova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):39-43. PubMed ID: 22500311 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical efficacy in antiepileptic drug trials. Schmidt D Epilepsy Res Suppl; 1991; 3():69-77. PubMed ID: 1777084 [No Abstract] [Full Text] [Related] [Next] [New Search]